AmycretinvsCagriSema

Amycretin is a unimolecular co-agonist that simultaneously activates both the GLP-1 receptor and the amylin (AMY) receptor — the first peptide engineered to combine these two complementary satiety pathways in a single molecule rather than as a two-drug combination. The design philosophy is to deliver the additive weight-loss benefit demonstrated by CagriSema (semaglutide + cagrilintide) without the manufacturing, dosing, and patient-acceptance complexities of co-formulating two separate drugs.

The GLP-1 component drives appetite suppression centrally through hypothalamic POMC/CART activation and NPY/AgRP inhibition, slows gastric emptying via vagal signalling, and stimulates glucose-dependent insulin secretion from pancreatic beta cells. The amylin component activates calcitonin-receptor/RAMP heterodimer complexes concentrated in the area postrema and nucleus tractus solitarius — brainstem regions outside the blood-brain barrier that form a parallel satiety circuit reducing meal size and food-seeking behaviour through neuroanatomically distinct pathways.

Because GLP-1 and amylin signal through different receptor families and target different neurons in the appetite control network, their effects are additive rather than redundant. Phase 1b/2a data showed up to 22% body weight reduction at 36 weeks for the subcutaneous form — comparable to CagriSema with a simpler one-molecule profile. A particularly notable feature is the parallel development of an oral formulation, which would be the first oral peptide combination therapy for obesity if approved. Novo Nordisk's branded development name is zenagamtide, and the molecule is positioned as the company's strategic answer to retatrutide and tirzepatide.

CagriSema exploits the principle that the brain's appetite regulation system has multiple independent signaling pathways, and targeting two of them simultaneously produces weight loss greater than either alone. The semaglutide component activates GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem, suppressing hunger through POMC neuron activation and NPY/AgRP neuron inhibition, while also slowing gastric emptying and improving glycemic control.

The cagrilintide component activates amylin receptors (CTR/RAMP complexes) in the area postrema and lateral parabrachial nucleus — brain regions that form a parallel but distinct satiety circuit. Amylin receptor signaling reduces meal size by promoting early satiation, whereas GLP-1 signaling primarily reduces between-meal hunger and food cravings. Together, they address both the desire to eat and the amount consumed per meal.

At the metabolic level, both components enhance insulin secretion and suppress glucagon in a glucose-dependent manner, but through separate pancreatic receptor populations. The combination also produces synergistic effects on gastric emptying, further reducing postprandial glucose spikes. Phase 3 trial data showed approximately 25% body weight loss — among the highest recorded for any pharmaceutical intervention — with the combination significantly outperforming either component alone, validating the dual-pathway hypothesis.